Reardon Andrew — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Reardon Andrew has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.90M.

Profile

Reardon Andrew

Andrew Reardon is the Chief Legal Officer and Secretary at Ligand Pharmaceuticals Inc, a biopharmaceutical company focused on drug discovery and development. He has been involved in the company through various SEC filings, indicating his role in corporate governance.

RoleCLO & Secretary
Notability20/100

Board memberships

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale600$317.15$190K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale900$315.78$284K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale100$314.58$31K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale700$313.46$219K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale1.1K$312.28$338K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale1.1K$311.72$349K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale104$310.20$32K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale396$308.99$122K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCM — Option exercise5.0K$52.27$261K
2026-07-06LGNDLIGAND PHARMACEUTICALS INCJ — Other acquisition / disposition132$160.71$21K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale200$230.41$46K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale1.2K$229.47$279K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale584$228.57$133K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale400$226.78$91K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale1.4K$225.97$324K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale677$225.20$152K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale491$223.95$110K
2026-06-02LGNDLIGAND PHARMACEUTICALS INCM — Option exercise5.0K$52.27$261K
2026-05-05LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale800$234.02$187K
2026-05-05LGNDLIGAND PHARMACEUTICALS INCS — Open-market sale1.4K$232.92$331K

Companies — Last 90 Days

Frequently Asked Questions

Who is Reardon Andrew?

Andrew Reardon is the Chief Legal Officer and Secretary at Ligand Pharmaceuticals Inc, a biopharmaceutical company focused on drug discovery and development. He has been involved in the company through various SEC filings, indicating his role in corporate governance.…

How many SEC Form 4 filings has Reardon Andrew submitted recently?

3 primary Form 4 filings in the last 90 days, covering 1 company.

Has Reardon Andrew been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 39 open-market sales ($5.90M) across all tracked filings.

Where can I see all of Reardon Andrew's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Reardon Andrew profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.